Search Results

OncoSynergy, Inc., a physician-founded oncology company committed to advancing therapeutics to address dire unmet medical needs, announced that the first patient was treated in the Company’s First-in-Human Phase 1 clinical trial evaluating OS2966 for the treatment of recurrent glioblastoma at Moffitt Cancer Center in Tampa, Florida.

Epsilogen, a global leader in the development of immunoglobulin E antibodies to treat cancer, announces the appointments of Ashley Nagle as Chief Business Officer and Peter Finan, currently a Non-Executive Director, as Non-Executive Chairman.